Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) CEO Lawrence Klein sold 25,000 shares of the firm's stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $95.60, for a total transaction of $2,390,000.00. Following the completion of the transaction, the chief executive officer directly owned 923,128 shares in the company, valued at $88,251,036.80. This represents a 2.64% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Lawrence Otto Klein also recently made the following trade(s):
- On Thursday, October 1st, Lawrence Klein sold 25,000 shares of Oruka Therapeutics stock. The stock was sold at an average price of $83.62, for a total value of $2,090,500.00.
- On Tuesday, September 15th, Lawrence Klein sold 2,452 shares of Oruka Therapeutics stock. The stock was sold at an average price of $95.71, for a total value of $234,680.92.
- On Tuesday, September 1st, Lawrence Klein sold 75,000 shares of Oruka Therapeutics stock. The shares were sold at an average price of $91.83, for a total value of $6,887,250.00.
Oruka Therapeutics Stock Performance
NASDAQ ORKA opened at $95.43 on Tuesday. The stock's 50 day simple moving average is $88.22 and its 200-day simple moving average is $69.23. Oruka Therapeutics, Inc. has a 1-year low of $25.23 and a 1-year high of $115.51.
Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.04). As a group, sell-side analysts forecast that Oruka Therapeutics, Inc. will post -2.42 EPS for the current year.
Wall Street Analyst Weigh In
Several brokerages have issued reports on ORKA. Wall Street Zen cut shares of Oruka Therapeutics from a "hold" rating to a "sell" rating in a research note on Sunday, August 16th. HC Wainwright reiterated a "buy" rating on shares of Oruka Therapeutics in a research report on Tuesday, October 27th. Weiss Ratings reissued a "sell (d-)" rating on shares of Oruka Therapeutics in a research note on Tuesday, October 13th. Wedbush restated an "outperform" rating and set a $165.00 price target on shares of Oruka Therapeutics in a research report on Tuesday, October 27th. Finally, Piper Sandler reaffirmed an "overweight" rating on shares of Oruka Therapeutics in a research note on Wednesday, October 7th. Ten research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $133.00.
Get Our Latest Stock Report on ORKA
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of ORKA. BlackRock Inc. purchased a new stake in shares of Oruka Therapeutics in the second quarter valued at about $474,916,000. Remedium Capital Partners LLC increased its position in Oruka Therapeutics by 0.9% during the first quarter. Remedium Capital Partners LLC now owns 1,565,661 shares of the company's stock worth $76,796,000 after purchasing an additional 13,247 shares during the last quarter. Jupiter Topco LLC purchased a new position in Oruka Therapeutics during the second quarter worth about $130,968,000. Avidity Partners Management LP raised its stake in Oruka Therapeutics by 15.1% during the first quarter. Avidity Partners Management LP now owns 760,424 shares of the company's stock worth $37,299,000 after purchasing an additional 100,000 shares during the period. Finally, Candriam S.C.A. raised its stake in Oruka Therapeutics by 2.6% during the first quarter. Candriam S.C.A. now owns 411,006 shares of the company's stock worth $20,160,000 after purchasing an additional 10,497 shares during the period. Hedge funds and other institutional investors own 56.44% of the company's stock.
Oruka Therapeutics Company Profile
(
Get Free Report)
Oruka Therapeutics, Inc (NASDAQ: ORKA) is a clinical-stage biopharmaceutical company developing long-acting antibody therapies for immune-mediated diseases. The company is focused on creating treatments that may provide durable disease control while reducing the frequency of administration compared with conventional biologic therapies.
Oruka's pipeline is centered on engineered monoclonal antibodies that target the interleukin-17 (IL-17) pathway, an important driver of inflammation in conditions such as psoriasis and other autoimmune diseases.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
